Read the News and Earn Credit - Click for Credit

Challenges in the Treatment of Acne in the United States

Bookmark and Share

CME/CE-Certified Supplement: Earn up to 2.5 CME/ 3.0 CE Credits

Please scroll to the bottom of the page to begin this activity.

Activity Information

Original Release Date: September 2015
Most Recent Review Date: September 2015
Expiration Date: September 30, 2017
Estimated Time to Complete Activity: 2.5 hours

Jointly provided by:

This activity is supported by an educational grant from:

  • Ranbaxy Laboratories Limited

Method of Participation

Participants should read the activity information, review the activity in its entirety, and complete the online post-test and evaluation. Upon completing this activity as designed and achieving a passing score on the post-test, you will be directed to a Web page that will allow you to receive your certificate of credit via email or you may print it out at that time. The online post-test and evaluation can be accessed at Inquiries may be directed to Global Academy for Medical Education or (973) 290-8225.

Target Audience

This supplement is intended for dermatologists, family practitioners, internists, nurse practitioners, physician assistants, and other clinicians who treat patients with with acne vulgaris.

Program Overview

Acne vulgaris, once thought of as an infectious dermatologic condition, now is recognized as a chronic inflammatory disease with a multifactorial pathogenesis. Research within the past decade has enhanced the understanding of several pathways involved in the expression of the underlying disease, including how Propionibacterium acnes induces inflammation, the role of the innate immune system in acne, and how aberrations in the immune response may be better addressed to manage this disease. As a result of this improved understanding, the goals of therapy also have evolved, and now include—in addition to managing acute outbreaks of acne lesions—prevention of visible lesions by reducing the development of microcomedones, managing underlying inflammation, reducing the risk for scarring, and minimizing the psychosocial burden of acne. Achieving these goals demands that clinicians remain up to date on the treatment recommendations of dermatology researchers and clinical experts, including which patients are candidates for isotretinoin therapy and what strategies can be helpful in promoting patient and family acceptance of this treatment and— for best results—adherence to a therapeutic regimen.

Learning Objectives

After reading and studying this enduring journal, participants will be better able to:

  • Discuss the safety and efficacy of the various classes of agents used for treating acne
  • Explain the mechanisms of action of systemic and topical agents used to treat acne
  • Diagnose and determine appropriate systemic and topical treatment options for patients with mild to severe acne
  • Describe the appropriate candidates for isotretinoin therapy, and incorporate improved protocols for the optimum use of this agent
  • Discuss strategies for minimizing the risk of acne scarring
  • Recognize the urgency of prompt treatment of acne to prevent physical and psychological scarring
  • Advise patients regarding the nature and management of their diseases and suggest practical psychosocial coping techniques
  • Implement educational strategies to improve adherence with treatment plans, including ways to help reduce relapse rates in adolescent patients

Accreditation Statements


This activity has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of The University of Louisville and Global Academy for Medical Education LLC. The University of Louisville is accredited by the ACCME to provide continuing medical education for physicians.

The University of Louisville Office of Continuing Medical Education & Professional Development designates this enduring material for a maximum of 2.50 AMA PRA Category 1 Credits. Physicians should claim only the credit commensurate with the extent of their participation in the activity.


This program has been approved by the Kentucky Board of Nursing for 3.0 contact hours through the University of Louisville Hospital, provider number 4-0068-7-16-820. The Kentucky Board of Nursing approval of an individual nursing education provider does not constitute endorsement of program content. Participants must complete the entire session, provide license, and complete the evaluation to receive contact hours.


Hilary E. Baldwin, MD
Medical Director
The Acne Treatment and Research Center
Morristown, New Jersey
Associate Professor of Clinical Dermatology
SUNY Downstate Medical Center Brooklyn,
New York

Guy F. Webster, MD, PhD
Clinical Professor
Department of Dermatology
Jefferson Medical College
Philadelphia, Pennsylvania

James J. Leyden, MD
Emeritus Professor of Dermatology
University of Pennsylvania
School of Medicine
Philadelphia, Pennsylvania

Andrea L. Zaenglein, MD
Professor Department of Dermatology
Department of Pediatrics
Hershey Medical Center
Pennsylvania State University
School of Medicine Hershey,

Disclosure Declarations

As a provider accredited by the ACCME, the Office of CME & PD, School of Medicine, University of Louisville must ensure balance, independence, objectivity, and scientific rigor in all its sponsored educational activities. All planners, faculty, reviewers, and other persons that affected the content of this CME activity were required to submit a financial disclosure form from which relevant conflicts of interest were determined.

Faculty Disclosures

Hilary E. Baldwin, MD, Consultant: Aqua Pharmaceuticals LLC, Promius Pharma, LLC, and Ranbaxy Laboratories Limited; Speakers Bureau: Allergan, Inc, Bayer Healthcare, Galderma Laboratories, L.P., Ranbaxy, and Valeant Pharmaceuticals North America LLC.

James J. Leyden, MD, Consultant: Allergan Inc, Anacor Pharmaceuticals Inc, Avon Products Company, Cutanea Life Sciences Pharmaceutical Company, Dow Pharma Solutions, Foamix Pharmaceuticals Ltd, Galderma, Ranbaxy, Sienna Biotec Pvt. Ltd, and Unilever Company.

Guy F. Webster, MD, PhD, Consultant: Aqua, Cutanea Life Sciences Pharmaceutical Company, Dermira, Galderma, Sebacea, Sienna Biotec Pvt. Ltd., and Valeant; Stock Owner: Dermira.

Andrea L. Zaenglein, MD, Consultant: Galderma, Promius, Ranbaxy, and Valeant; Grant/Research: Anacor Pharmaceuticals and Stiefel Laboratories, Inc.

Global Academy for Medical Education Staff: Sylvia H. Reitman, MBA, DipEd; Shirley V. Jones, MBA; and Joanne Still, BA have no relevant financial relationships to disclose

Off Label/Investigational-Use Disclosure

his activity discusses the off-label use of spironolactone for acne and isotretinoin for acne that may be physically or psychologically scarring.

This continuing education supplement was developed from a clinical roundtable with the faculty. The Guest Editors acknowledge the editorial assistance of Global Academy for Medical Education and Joanne Still, medical writer, in the development of this supplement. The manuscript was reviewed and approved by the Guest Editors as well as the Editors of Seminars in Cutaneous Medicine and Surgery. The ideas and opinions expressed in this supplement are those of the Guest Editors and do not necessarily reflect the views of the supporters, Global Academy for Medical Education, the University of Louisville, or the Publisher.

Download PDF

Supplement to Seminars in Cutaneous Medicine and Surgery
Supplement to Dermatology News


Copyright © 2015 by Frontline Medical Communications Inc. No part of this publication may be reproduced or transmitted in any form or by any means, electronic or mechanical, including photocopy, recording, or any information storage and retrieval system, without written permission from the Publisher. Printed in the United States of America.

AcneSppl_final.pdf2.2 M
click me